Data from the present study suggest that basal insulin plus OHA therapy rapidly corrects hyperglycemia and also confers β-cell function benefits, possibly by eliminating glucotoxicity and providing a β-cell rest period. The gene discussed is INS; the disease is Hyperglycemia.